What changed in cancer care after Keytruda (pembrolizumab) got approved?
Keytruda (pembrolizumab) is an immune checkpoint inhibitor that blocks PD-1, helping the immune system attack cancer cells. Since its approvals, it has expanded treatment options across many cancer types, including diseases where earlier standard care relied on chemotherapy or targeted therapies rather than immunotherapy. Its uptake has also reshaped treatment sequencing, with immunotherapy moving earlier in many settings depending on tumor type, biomarker status, and risk profile.
Keytruda’s main clinical impact comes from durable responses in a subset of patients and, in several cancers, improved outcomes compared with previous standard treatments. It has also made biomarker-driven treatment more common in routine oncology care (for example, testing tumors for PD-L1 expression in cancers where that helps guide decisions) [1][2].
How has Keytruda affected survival outcomes and response rates?
Across multiple tumor types, Keytruda has been used in different lines of therapy, from advanced disease to earlier stages, using evidence from clinical trials and subsequent approvals. Many studies have shown meaningful response rates and the potential for long-lasting remissions in patients who respond [1].
In cancers where comparisons were available, Keytruda improved key endpoints (such as overall survival and/or progression-free survival) versus prior approaches in specific settings, which helped establish immunotherapy as a standard option for appropriate patients [1][2].
Which cancers has Keytruda most changed, and where does it fit today?
Keytruda has had major influence in several cancers, including melanoma and lung cancers, where it has been a cornerstone immunotherapy option for many patients. It has also been incorporated into treatment strategies for other solid tumors and some hematologic malignancies as approvals expanded over time [1][2].
Its role varies by cancer type and stage:
- In some diseases, it is used as monotherapy.
- In others, it is combined with chemotherapy or other immunotherapies to improve response rates and deepen benefit [1][2].
Because approvals grew over time and were tailored to trial results, “how it fits” depends on the specific cancer, line of therapy, and biomarker status.
Why do clinicians and patients associate Keytruda with PD-L1 testing and biomarker decisions?
Keytruda’s performance can vary by tumor biology. For some cancers, PD-L1 expression helps predict which patients are more likely to benefit, so testing became part of standard decision-making in many settings. That pushed more routine biomarker evaluation into everyday oncology workflows, often alongside treatment selection and eligibility for specific regimens [1][2].
What side effects or risks have shaped how Keytruda is used?
Like other PD-1 inhibitors, Keytruda can cause immune-related adverse events because it activates the immune system. These can affect organs such as the skin, colon, liver, endocrine glands, lungs, and others. Management typically involves prompt recognition and treatment (often with corticosteroids and treatment interruption depending on severity) [1][2].
This safety profile has influenced clinical practice by increasing emphasis on:
- monitoring during treatment,
- patient education about symptoms that should prompt urgent evaluation,
- and standardized management pathways for immune-related toxicities [1][2].
How has Keytruda changed the future direction of immunotherapy?
Keytruda’s success helped validate checkpoint inhibition as a durable-treatment strategy across multiple cancers, driving further research into combination regimens and earlier use. It also accelerated the development and approval of additional immunotherapies and combinations, including regimens that pair PD-1 blockade with chemotherapy or other agents [1][2].
Where uncertainty still exists for patients?
Even with broad impact, not all patients benefit. Response rates are often highest in certain biomarker-defined groups, and some patients experience toxicity without clear benefit. Researchers continue to refine patient selection, combination strategies, and sequencing to improve outcomes for those who do not respond to PD-1 therapy alone [1][2].
---
Sources:
[1] https://www.merck.com/our-impact/medicine/oncology/KEYTRUDA/
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/keytruda-pembrolizumab